New Hologic CEO aims for Dx revenue growth over sale option

On the way in the door as the new CEO of Hologic ($HOLX), Stephen MacMillan said he would oversee further growth of the women's diagnostic medical imaging and surgical products company, despite Hologic's recent efforts to reorganize. With the guiding hand of Carl Icahn, who recently grabbed 12.6% of Hologic's shares, the M&A option was rumored to be on the table, but it looks as if the company will first aim to boost revenue if MacMillan, the former CEO of Stryker ($SYK), can make it happen. More from FierceDiagnostics

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.